The largest database of trusted experimental protocols

10 protocols using kasumi 1 cells

1

Culturing and Modulating Hematopoietic Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Kasumi-1 cells (ATCC, Manassas, VA) were cultured in RPMI-1640 (Lonza, Walkersville, MD) supplemented with 10% FBS (Sigma, St Louis, MO) and 1% Penicillin/Streptomycin (Invitrogen, Carlsbad, CA). HL60 cells (ATCC) were cultured in MEMα (Invitrogen) supplemented with 20% FBS and 1% Penicillin/Streptomycin. All cells were maintained at 37 °C and 5% CO2 at concentrations of 106 cells/mL. When indicated, cells were also cultured with the following: 10 uM all-trans retinoic acid (Sigma), 50 uM indomethacin (Sigma), 100 uM cytarabine (Abcam, Cambridge, MA), 0.1 uM vitamin D3 (Sigma), 10 nM recombinant human Wnt3a (R&D Systems, Minneapolis, MN), or 10 nM ICG-001 (Selleck Chemical, Houston, TX). Non-targeting scramble control and TLE4-specific shRNA constructs were developed and delivered to cells via lentiviral delivery as previously described [10 (link)]. The shRNA used and their target sequences were: shTLE4 1 (AGTGATGACAACTTGGTGG) and shTLE4 2 (GGCATTATGTCATGTATTA). Data in figures were obtained using shTLE4 2 unless otherwise indicated. Infected cells were identified by GFP fluorescence detected using FACS LSRII or selected for via cell sorting with FACS Aria (BD, San Jose, CA). Full-length TLE4 (a.k.a.KIAA1261 kind gift of Dr. Ohara [18 (link)]) cDNAs were cloned into the MSCV-IRES-GFP retroviral vector.
+ Open protocol
+ Expand
2

NR4A1 Gene Overexpression in Kasumi-1 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Kasumi-1 cells were purchased from ATCC. Cells were maintained in 1640 RPMI with 20% FBS. The plasmids and In-vitro transcribed RNA (IVT-RNA) transfection system have been previously described [15 ]. In-vitro transcription (IVT) was performed per manufacturer’s instructions on linearized plasmid containing the NR4A1 coding sequence using the mMESSAGE mMACHINE® T7 Kit (Applied Biosystems). RNA polyadenylation was performed with a Poly(A) Tailing Kit, and resulting IVT-RNA was purified with a MEGA Clearance Kit (Applied Biosystems) according to manufacturer instructions. For electroporation, cells were suspended to a final concentration of 1 million cells per 100uL DPBS. 200uL of cell solution was transferred to 0.4 cm cuvettes (USA Scientific), mixed by pipetting with IVT-RNA at a final concentration of 100 nM, and immediately electroporated at 330V for 5 milliseconds with the GenePulser Xcell system (Bio-Rad).
+ Open protocol
+ Expand
3

Establishment of Cabozantinib-Resistant AML Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
The human AML cell lines Molm13 (DSMZ, Brauschweig, Germany) and MV4-11 (DSMZ) were maintained in Roswell Park Memorial Institute (RPMI)-1640 medium (ThermoFisher Scientific/Gibco, Waltham, MA, USA), containing 10% fetal bovine serum (FBS); Kasumi-1 cells (ATCC, Manassas, VA, USA) were cultured in RPMI-1640 medium containing 20% FBS. The cabozantinib-resistant cell line, Molm13-XR, was established by culturing Molm13 cells in the presence of increasing concentrations of cabozantinib. The stable resistant cell line was then maintained in a complete RPMI-1640 medium with 10% FBS, in the absence of cabozantinib. Cell lines were cultured at 37 °C in a humidified atmosphere containing 5% CO2. The genetic profiles of these cell lines were authenticated (16-markers short tandem repeat) by the Food Industry Research and Development Institute (Hsinchu, Taiwan), and were found to be identical to their reported generic profiles.
Cabozantinib-malate, pyrvinium pamoate, and rapamycin were purchased from Selleck Chemicals (Houston, TX, USA), Sigma-Aldrich/Merck (Darmstadt, Germany), and TargetMol (Boston, MA, USA), respectively.
+ Open protocol
+ Expand
4

AML and CML Cell Samples Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
FLT3(ITD);TET2mut, FLT3(ITD);AML1-ETO and AML1-ETO –positive primary AML samples were from the ECOG-ACRIN E1900 clinical trial (Patel et al., 2012 (link)). JAK2(V617F);TET2mut and BRCA1/2-deficient AML samples were described before (Nieborowska-Skorska et al., 2017a (link), 2017b (link)). BCR-ABL1 –positive CML-CP samples were obtained from the Medical University of Vienna and Ludwig-Boltzmann Institute for Hematology and Oncology, Vienna, Austria. Samples of normal hematopoietic cells were purchased from StemCell Technologies (Vancouver, Canada). LinCD34+ cells were obtained from mononuclear fractions by magnetic sorting using the EasySep Lin negative selection cocktail followed by CD34 positive selection (StemCell Technologies) as described before (Nieborowska-Skorska et al., 2017b (link)). CML-BP K562 cells, AML MV4–11 cells and Kasumi-1 cells were from ATCC. TGFβR2 CRISPR/Cas9 knock-down K562-Cr cells were from Applied Biological Materials Inc. (Vancouver, Canada). These leukemic cell lines were maintained in DMEM supplemented with 10% FBS, L-glutamine and antibiotics in 37°C.
+ Open protocol
+ Expand
5

Culturing Kasumi-1 Cells for Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
Kasumi-1 cells (ATCC) were cultured in RPMI (Gibco) supplemented with 20% fetal calf serum (FCS, HyClone), 2 mM GlutaMAX (Gibco), 100 units/mL penicillin, and 100 μg/mL streptomycin (Gibco). Cells were cultured at 5% CO2 and 37 °C. Cell lines were tested monthly for mycoplasma contamination.
+ Open protocol
+ Expand
6

Cell Culture Conditions for Leukemia Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cbfb+/56M, Mx1-Cre+ cells were cultured in RPMI-1640 (ATCC, Manassas, Virginia) supplemented with 20% ES cell qualified fetal bovine serum (Thermo Fisher Scientific, Waltham, MA) 1% penicillin/streptomycin, 1% L-glutamine, 10 ng/mL IL-3, 10 ng/mL IL-6, 20 ng/mL SCF (Peprotech, Rocky Hill, NJ) and cryopreserved in RPMI-1640 supplemented with 50% FBS and 10% DMSO. COS-7 cells (ATCC) and HEK293T cells (ATCC) were maintained in DMEM supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 1% L-glutamine. ME-1 cells (kindly provided by P. Liu, NHGRI/NIH) were maintained in RPMI-1640 supplemented with 20% fetal bovine serum, 2.5% of a 10% (w/v) glucose solution, 1% penicillin/streptomycin, 1% L-glutamine, 1% sodium pyruvate, and 2.5% 1M HEPES. Kasumi-1 cells (ATCC) were maintained according to ATCC recommended protocol. Leukemia cell lines were validated by karyotype analysis by the UNMC Human Genetics Laboratory and/or western blot analysis. Cells were maintained in culture for less than 3 months at 37°C, 5% CO2 and routinely monitored for Mycoplasma contamination using MycoAlert PLUS Mycoplasma Detection Kit (Lonza).
+ Open protocol
+ Expand
7

Culturing Human Hematopoietic Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Kasumi-1 cells (ATCC CRL-2724), HL60 cells (ATCC CCL-240), THP-1 cells (ATCC TIB-202) and U937 cells (CRL-1593) were purchased from ATCC. Cells were cultured following the manufacturer’s culture method. Kasumi cells were cultured with RPMI-1640 growth medium (Gibco, 11875093) containing 20% FBS. HL-60 cells were cultured with IMDM containing 20% FBS (Thermofisher 12440053). THP-1 cells were cultured with RPMI-1640 containing 10% FBS. U937 cells were cultured with RPMI-1640 containing 10% FBS.
+ Open protocol
+ Expand
8

Establishing CCND2 AML Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
KG1a and Kasumi-1 cells (both CCND1 and CCND2 wild-type) were obtained from the American Type Culture Collection (ATCC, Manassas, VA) for studying the effects of the CCND2 Thr280Ala mutation in AML. Both cell lines were authenticated by ATCC using the cytochrome C oxygenase 1 gene (COI) assay for interspecies determination, and short tandem repeat (STR) analysis for intraspecies determination of the unique DNA profiles. The cells were cultured in RPMI medium supplemented with 10% Fetal Bovine Serum (FBS) and 1% Antibiotic-Antimycotic (Gibco, Big Cabin, OK).
+ Open protocol
+ Expand
9

Cell Line Maintenance and Synchronization

Check if the same lab product or an alternative is used in the 5 most similar protocols
Kasumi-1 cells were obtained from American Type Culture Collection (ATCC). MV4–11 and K562 cells were gifts from Emery Bresnick. THP-1 cells were a gift from David Beebe. All cell lines were validated at UW-Madison using polymorphic short tandem repeat loci and were free of mycoplasma. All cell lines were maintained at 37°C and 5% CO2 in a humidified incubator in RPMI 1640 medium containing 2 mM L-glutamine, supplemented with 100 units/mL penicillin-streptomycin and 10% (THP-1, K562 and MV4–11) or 20% (Kasumi-1) fetal bovine serum.
For thymidine synchronization, cells were challenged with 2.5 mM thymidine for 24 h, washed once with HBSS, then replenished with normal media for 8 h prior to further chemical treatments.
+ Open protocol
+ Expand
10

Kasumi-1 Cells for AML-M2 Translocation Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
Kasumi-1 cells (12 (link)), derived from the peripheral blood of a 7 year old Japanese male who was diagnosed with AML-M2, were purchased from the American Type Culture Collection (Manassas, VA, USA) and were maintained in RPMI-1640 with 20% fetal bovine serum (Gibco). The genetic characteristics of this cell line include a chromosome t(8;21) (q22;q22) translocation, thus making it a good research tool for investigating this type of translocation in leukemia. The cell line was incubated in a 37°C humidified atmosphere with 5% CO2. Different concentrations of ZGDHu-1 (50, 100, 200, 500 and 1,000 μg/l) and controls (negative control and DMSO as solvent control) were added to the Kasumi-1 cells.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!